Pipeline

Addressing unmet needs in solid tumor and blood cancers

Pipeline-banner

Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with cancers.

The recent approval of TRODELVY highlights the potential of our ADC platform and strengthens the premise that the Trop-2 antigen found on many solid tumors is an important target for drug delivery.

To address virtually every stage of triple-negative breast cancer treatment, while enhancing our competitive positioning in metastatic urothelial cancer and HR+/HER2‒ metastatic breast caner, we have diverse and robust clinical studies for TRODELVYTM either as a monotherapy or in combination with other agents, as well as exploring its effectiveness in other Trop-2-expressing cancers.

Multiple TRODELVYTM programs to address unmet needs in Trop-2-expressing cancers

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate that directs the delivery of SN-38 to the protein Trop-2 that is found in many types of solid tumors.

Indication Designation Phase 1 Phase 2 Phase 3 Approval Partner  
mTNBC(3L) ASCENT
 
 
 
 
   
Description

A Phase 3 study in patients with metastatic triple-negative breast cancer refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for metastatic disease.

Learn More
HR+/HER2 - mBC TROPiCS-02
 
 
 
 
   
Description

A Phase 3 study in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who have failed at least 2 prior chemotherapy regimens.

Learn More
mTNBC(3L)(China)  
 
 
 
 
Everest  
Description

A registration-oriented Phase 2b study in Chinese patients with metastatic triple-negative breast cancer who are refractory or relapsing after at least 2 prior standard chemotherapy regimens for unresectable, locally advanced or metastatic disease.

Learn More
mTNBC(1L)/mUC/mNSCLC(+Tecentriq) MORPHEUS
 
 
 
 
Roche  
Description

A Phase 1b/2 study in combination with atezolizumab, an anti-programmed death-ligand 1 antibody, in patients with metastatic triple-negative breast cancer. This study has been expanded into metastatic urothelial cancer and metastatic non-small cell lung cancer

Learn More
mTNBC/mUC/Ovarian(+Rubarca) SEASTAR
 
 
 
 
Clovis Oncology  
Description

A Phase 1b/2 study in combination with rucaparib, a PARP inhibitor, in patients with an advanced/metastatic solid malignancy, including triple-negative breast, urothelial, and ovarian cancers.

Learn More
mUC(3L) TROPiCS-04
 
 
 
 
   
Description

A Phase 3 study in patients with metastatic urothelial cancer who have progressed after prior therapy with platinum-based regimen and anti-programmed cell death protein 1/programmed death-ligand 1 therapy.

Learn More
mUC(3L) TROPHY U-01
 
 
 
 
   
Description

A Phase 2 study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-programmed cell death protein 1/programmed death-ligand 1 therapy

Learn More
mNSCLC/H&N TROPiCS-03
 
 
 
 
   
Description

A multi-cohort Phase 2 study in patients with metastatic non-small cell lung cancer, recurrent endometrial cancer and squamous carcinoma of the head and neck.

Learn More